Fujian Guangsheng Zhonglin Biotechnology

Fujian Guangsheng Zhonglin Biotechnology is a Chinese biopharmaceutical company and a subsidiary of Fujian Cosunter Pharmaceutical. The company specializes in the development of innovative small molecule drugs, with a primary focus on anti-infectives, oncology, and inflammatory diseases. Its most notable achievement is the development of Taizhongding (GST-HG171), a 3CL protease inhibitor that received conditional marketing approval in China for the treatment of COVID-19. The company's pipeline also includes promising candidates targeting the NLRP3 inflammasome for metabolic diseases and c-Met for various cancers. By leveraging the resources of its parent company, Fujian Guangsheng Zhonglin Biotechnology integrates research, clinical development, and commercialization capabilities.